Raltegravir has nearly two decades of evidence behind it, beginning with trials in people who had run out of options and extending into first-line and pregnancy use.
What did BENCHMRK test?
Raltegravir added to an optimised background regimen in heavily treatment-experienced people with resistance to three drug classes. A far higher proportion achieved viral suppression than on the background regimen alone, which was a striking result in a group with very poor prospects.
Why did that matter so much?
Because it demonstrated that a new class delivered real benefit to people for whom nothing else worked. It changed the prognosis for a cohort who had exhausted the available options, and it validated integrase as a target.
What did STARTMRK show?
Raltegravir compared with efavirenz in people starting treatment. Suppression was comparable or better, achieved faster, with substantially fewer neuropsychiatric side effects and a more favourable lipid profile. Five-year follow-up maintained that picture.
What did the once-daily studies show?
A higher-dose formulation taken once daily as two tablets was compared with the standard twice-daily dosing and found non-inferior. That addressed the main practical objection to the drug without changing anything else about it.
How does it compare with dolutegravir?
The SPRING-2 trial compared them directly in people starting treatment and found them comparable for suppression. Dolutegravir's advantages are once-daily dosing, availability in single-tablet regimens and a higher resistance barrier rather than greater potency.
What does the resistance data show?
A lower barrier than dolutegravir or bictegravir. Raltegravir resistance can emerge through a single mutation in some pathways, and virus resistant to it may still respond to dolutegravir, particularly at twice-daily dosing.
What about tolerability?
Consistently excellent across studies. Raltegravir has among the lowest rates of discontinuation for adverse events of any antiretroviral, which is why it is frequently chosen for people who have not tolerated something else.
What about lipids?
Favourable. Studies have found lower cholesterol and triglycerides than on efavirenz or boosted protease inhibitors, and switching to it from those regimens improved lipids.
What about weight?
Weight gain has been reported across integrase inhibitors and appears less pronounced with raltegravir than with dolutegravir or bictegravir in some analyses. The comparisons are not conclusive and the difference is worth knowing about.
What about pregnancy?
A substantial body of evidence, including use late in pregnancy where rapid viral load reduction is needed. Its safety record and minimal interaction profile make it one of the better established options in that setting.
What about tuberculosis co-treatment?
Studies have examined raltegravir alongside rifampicin at increased doses, with reasonable results. It is one of a small number of antiretrovirals that can be combined with tuberculosis treatment at all.
What about long-term safety?
Nearly two decades of cohort data have not identified organ toxicity attributable to it. Rhabdomyolysis and severe skin reactions have been reported rarely, which is the expected pattern for a widely used drug.
What does real-world data show?
Consistent with the trials: low discontinuation, good tolerability, and continued use in the specific niches where its interaction profile matters.
What is still being studied?
Relatively little, since attention has moved to newer integrase inhibitors. Ongoing work concerns its role in pregnancy and in people with complex co-medication.
Where can you read the evidence yourself?
NAM aidsmap summarises HIV research reliably, and the British HIV Association publishes the guidelines UK clinicians follow. Both are freely available and considerably more useful than a general search.